Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Gold Miners ETF (GDX) vs Incyte Corporation (INCY) Price & Performance

VanEck Gold Miners ETFTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

VanEck Gold Miners ETF vs Incyte Corporation — how do they compare? VanEck Gold Miners ETF trades at $90.97, while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.

GDXINCY
52-Week High
$115.84$129.93
52-Week Low
$56.60$81.61
Market Cap
$24.54B
Sector
Health
Enterprise Value
$20.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Gold Miners ETF

GDX (VanEck Gold Miners ETF) trades at $90.96, up 0.52% with a bullish technical signal from moving averages but overbought RSI readings. The ETF benefits from gold's seven-week rally to near $4,300/oz, though mining stocks have lagged the metal's gains. Recent institutional activity shows mixed sentiment with City Holding reducing its position by 85.8% while Axiom Investment added a $934,000 stake in Q1 2026.

Gold miners offer leveraged exposure to rising gold prices with attractive valuations, but face volatility risks. The sector's free cash flow yields are at record highs, supporting potential upside if gold sustains momentum. Key risks include gold price sensitivity, mining operational challenges, and competition from physical gold ETFs with lower expense ratios.

Incyte Corporation

Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.

The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Gold Miners ETF

The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.

Read more on GDX

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY